Cargando…
Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs
There is a clinical need for conceptually new treatments that target the excessive activation of inflammatory pathways during systemic infection. Thrombin-derived C-terminal peptides (TCPs) are endogenous anti-infective immunomodulators interfering with CD14-mediated TLR-dependent immune responses....
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541425/ https://www.ncbi.nlm.nih.gov/pubmed/37773180 http://dx.doi.org/10.1038/s41467-023-41702-y |
_version_ | 1785113902998093824 |
---|---|
author | Petruk, Ganna Puthia, Manoj Samsudin, Firdaus Petrlova, Jitka Olm, Franziska Mittendorfer, Margareta Hyllén, Snejana Edström, Dag Strömdahl, Ann-Charlotte Diehl, Carl Ekström, Simon Walse, Björn Kjellström, Sven Bond, Peter J. Lindstedt, Sandra Schmidtchen, Artur |
author_facet | Petruk, Ganna Puthia, Manoj Samsudin, Firdaus Petrlova, Jitka Olm, Franziska Mittendorfer, Margareta Hyllén, Snejana Edström, Dag Strömdahl, Ann-Charlotte Diehl, Carl Ekström, Simon Walse, Björn Kjellström, Sven Bond, Peter J. Lindstedt, Sandra Schmidtchen, Artur |
author_sort | Petruk, Ganna |
collection | PubMed |
description | There is a clinical need for conceptually new treatments that target the excessive activation of inflammatory pathways during systemic infection. Thrombin-derived C-terminal peptides (TCPs) are endogenous anti-infective immunomodulators interfering with CD14-mediated TLR-dependent immune responses. Here we describe the development of a peptide-based compound for systemic use, sHVF18, expressing the evolutionarily conserved innate structural fold of natural TCPs. Using a combination of structure- and in silico-based design, nuclear magnetic resonance spectroscopy, biophysics, mass spectrometry, cellular, and in vivo studies, we here elucidate the structure, CD14 interactions, protease stability, transcriptome profiling, and therapeutic efficacy of sHVF18. The designed peptide displays a conformationally stabilized, protease resistant active innate fold and targets the LPS-binding groove of CD14. In vivo, it shows therapeutic efficacy in experimental models of endotoxin shock in mice and pigs and increases survival in mouse models of systemic polymicrobial infection. The results provide a drug class based on Nature´s own anti-infective principles. |
format | Online Article Text |
id | pubmed-10541425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-105414252023-10-01 Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs Petruk, Ganna Puthia, Manoj Samsudin, Firdaus Petrlova, Jitka Olm, Franziska Mittendorfer, Margareta Hyllén, Snejana Edström, Dag Strömdahl, Ann-Charlotte Diehl, Carl Ekström, Simon Walse, Björn Kjellström, Sven Bond, Peter J. Lindstedt, Sandra Schmidtchen, Artur Nat Commun Article There is a clinical need for conceptually new treatments that target the excessive activation of inflammatory pathways during systemic infection. Thrombin-derived C-terminal peptides (TCPs) are endogenous anti-infective immunomodulators interfering with CD14-mediated TLR-dependent immune responses. Here we describe the development of a peptide-based compound for systemic use, sHVF18, expressing the evolutionarily conserved innate structural fold of natural TCPs. Using a combination of structure- and in silico-based design, nuclear magnetic resonance spectroscopy, biophysics, mass spectrometry, cellular, and in vivo studies, we here elucidate the structure, CD14 interactions, protease stability, transcriptome profiling, and therapeutic efficacy of sHVF18. The designed peptide displays a conformationally stabilized, protease resistant active innate fold and targets the LPS-binding groove of CD14. In vivo, it shows therapeutic efficacy in experimental models of endotoxin shock in mice and pigs and increases survival in mouse models of systemic polymicrobial infection. The results provide a drug class based on Nature´s own anti-infective principles. Nature Publishing Group UK 2023-09-29 /pmc/articles/PMC10541425/ /pubmed/37773180 http://dx.doi.org/10.1038/s41467-023-41702-y Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Petruk, Ganna Puthia, Manoj Samsudin, Firdaus Petrlova, Jitka Olm, Franziska Mittendorfer, Margareta Hyllén, Snejana Edström, Dag Strömdahl, Ann-Charlotte Diehl, Carl Ekström, Simon Walse, Björn Kjellström, Sven Bond, Peter J. Lindstedt, Sandra Schmidtchen, Artur Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs |
title | Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs |
title_full | Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs |
title_fullStr | Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs |
title_full_unstemmed | Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs |
title_short | Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs |
title_sort | targeting toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541425/ https://www.ncbi.nlm.nih.gov/pubmed/37773180 http://dx.doi.org/10.1038/s41467-023-41702-y |
work_keys_str_mv | AT petrukganna targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT puthiamanoj targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT samsudinfirdaus targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT petrlovajitka targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT olmfranziska targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT mittendorfermargareta targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT hyllensnejana targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT edstromdag targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT stromdahlanncharlotte targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT diehlcarl targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT ekstromsimon targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT walsebjorn targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT kjellstromsven targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT bondpeterj targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT lindstedtsandra targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs AT schmidtchenartur targetingtolllikereceptordrivensystemicinflammationbyengineeringaninnatestructuralfoldintodrugs |